Gingivitis is a common, mild form of gum disease characterized by inflammation, redness, and bleeding of the gums, affecting 40%-70% of patients during the gestational period. It accounts for a significant portion of oral health issues globally. There is a high unmet clinical need for better therapies, as current treatments primarily involve oral hygiene practices and antiseptic mouthwashes. Emerging gingivitis drug candidates, including anti-inflammatory agents and antimicrobial therapeutics, offer promising potential. The growing focus on preventive dental care is likely to support pipeline growth, driving innovation and improving outcomes in the coming years.
Major companies involved in the gingivitis pipeline drugs market include Colgate Palmolive, GlaxoSmithKline, and others.
Leading drugs currently in the pipeline include Chlorhexidine Toothpaste, Povidone-Iodine Solution, and others.
The rising prevalence of gingivitis during pregnancy, advancements in anti-inflammatory therapies, and increased focus on preventive dental care are expected to positively impact the gingivitis pipeline landscape.
The Gingivitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into gingivitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gingivitis. The gingivitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The gingivitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with gingivitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to gingivitis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Gingivitis is a mild, reversible form of gum disease caused by plaque accumulation along the gumline. It occurs when bacteria in plaque trigger gum inflammation, leading to redness, swelling, and bleeding, especially during brushing or flossing. Poor oral hygiene is the primary cause, but smoking, diabetes, and hormonal changes can also increase the risk of gingivitis.
Gingivitis treatment involves removing plaque and reducing inflammation. Professional dental cleanings, including scaling and root planing, help eliminate tartar buildup. Daily oral hygiene, such as brushing twice, flossing, and using an antiseptic mouthwash, is crucial. Dentists may prescribe antibiotics for persistent infections. Lifestyle changes, like quitting smoking and maintaining a healthy diet, also support recovery.
Gingivitis, an early stage of periodontal disease, commonly affects 40%-70% of individuals during the gestational period. In the United States, about 4 in 10 adults aged 30 and older experience periodontitis. In Japan, 8.6 million people received treatment for gingivitis in 2020. In India, the prevalence of periodontal disease is 51%, highlighting the growing need for effective treatments.
This section of the report covers the analysis of gingivitis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total gingivitis clinical trials.
The drug molecule categories covered under the gingivitis pipeline analysis include small molecules, biologics, peptides, monoclonal antibodies, and natural compounds. The gingivitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gingivitis.
The EMR report for the gingivitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed gingivitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in gingivitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for gingivitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of gingivitis drug candidates.
Chlorhexidine Toothpaste (0.3%), sponsored by Colgate-Palmolive, is being evaluated in a Phase III clinical study to assess its effectiveness in reducing gingival inflammation in patients with dental plaque and gingivitis. This randomized, double-blind trial involves around 80 participants aged 18-70 and is expected to be completed by April 2025.
Povidone-iodine, a topical antiseptic known for its antimicrobial properties, is being investigated in a Phase II study conducted by the University of Washington. The study aims to assess the efficacy and safety of 10% Povidone-iodine in preventing white spot lesions and gingival inflammation in orthodontic patients aged 10-17. The study, involving approximately 80 participants, is expected to conclude by March 2027.
Ginger mouthwash, known for its anti-inflammatory properties, is being investigated in a Phase II study sponsored by Al-Mustansiriyah University for its potential benefits in treating gingivitis in pregnant women under stress. The study aims to assess the effectiveness of ginger mouthwash in reducing gingival inflammation and lowering salivary biomarkers such as IL-6 and cortisol, which are indicators of inflammation and stress. The ginger mouthwash will be compared with chlorhexidine and a placebo to determine its relative efficacy. The study is expected to conclude by April 20, 2025, and is expected to enroll 51 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Gingivitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for gingivitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into gingivitis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share